The genetic factors that predispose to Alzheimer's disease (AD) are heterogeneous. Two recent reports have suggested that a mitochondrial DNA mutation within the tRNAGln gene, located at position 4336, may be a risk factor for AD, as it was found in 10/256 (3.9%) cases with AD confirmed by necropsy. Although low prevalences ofthis mutation were detected in non-demented subjects in both of these studies, the controls were not carefully matched with the AD cases. We have investigated the frequency ofthis mutation in two community based elderly cohorts in Cambridgeshire, who have participated in longitudinal studies of cognitive function. The 4336 mitochondrial mutation was detected in 8/ 443 people examined. These people were found to be non-demented at ages 74, 81, 84, 86, 89, 90, 91, and 102 years, in contrast to the previously described cases whose onset of dementia occurred between 60 and 76 years (mean 68). Accordingly, we believe that this mitochondrial variant is not a high penetrance mutation which predisposes to dementia before the age of 76
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Alzheimer's disease (AD) is a neurodegenerative disorder resulting in progressive cognitive decline and dementia. The disorder may be broadly categorised into two groups according to the age of onset.1 An age cut off of 60 or 65 years has been used to distinguish early onset from late onset cases, although these are indistinguishable neuropathologically. (2) The second, distinct, study group came from a 10 year longitudinal study of cognitive function and ageing.28 Participants were originally aged 75 and over, identified from population registers for family practitioners in the city of Cambridge. The participants had taken part in at least three further screening interviews since baseline: 2.4 years, 6 years, and 10 years. These interviews included Mini-Mental State Examinations. In this 10 year follow up, of the original 1968, 546 who had taken part in the previous follow ups were available for interview. Of these, 83% (446) agreed to be seen and successful venepuncture was carried out on 63% of these, 182 females and 100 males. These represent a sample of people who were all aged 84 or older at the time ofvenepuncture.
These studies have been approved by the ethics committee at Addenbrooke's Hospital. Informed consent was given by all cases who were investigated. These people were all formally evaluated before DNA testing.
PCR AND RESTRICTION ENZYME ANALYSIS DNA was extracted from mouthwash cell pellets by phenol extraction (population 1) or from venous blood (population 2). A short fragment of 288 bp was amplified by PCR, with primers which were designed using OLIGO Primer Analysis Software (National Biosciences, Inc). The primers were located at positions 4230 to 4250 bp (4230F: 5' CAT TAC AAT CTC CAG CAT TCC 3') and 4517 to 4497 bp (4517R: 5' GCC TGC AAA GAT GGT AGA GTA 3'), according to the designation used by Anderson et al. 29 The PCR reaction contained 50 mmol/l KCl, 10 mmol/l Tris-HCl, pH 8.0, at room temperature, 2.5 mmol/l MgCl2, 0.01% gelatin, 30 ng of each primer, 250 mol/l of each dNTP, and 0.3 U of Taq polymerase (Gibco BRL). The cycle parameters, performed on a Hybaid Thermocycler, were three minutes initial denaturation at 940C followed by 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for one minute. Restriction digestion was carried out by the direct addition of 1.7 U of AvaII (New England Biolabs), diluted in 1 x PCR buffer, to each PCR reaction, followed by overnight digestion at 37°C. DNA fragments were separated on a 1 % agarose gel.
The presence of an AvaII restriction site within this PCR product implied the 4336 A to G mutation. The exact position and sequence of this variant was confirmed using an allele specific mutagenically separated PCR (MS PCR) assay.30 Two allele specific primers were designed at positions 4356 to 4336 bp (MT4336WT: 5' GGG ATG GGT TCG ATT CTC AAA 3') and 4376 to 4336 bp (MT4336M 5' CGG AGA ATT TTG GAT TCT CAC CGATGGGTTCGATTC TGA TG 3'). Amplification using both of these primers in conjunction with primer 4230F resulted in PCR fragments of 127 bp or 147 bp respectively according to whether an A or G was present at position 4336. PCR products were sized on a 2% agarose/1% NuSieve gel.
Apo E genotypes were determined using the method of Hixson and Vernier"3 and restriction fragments were visualised by silver staining. specifically when an A is present at position 4336, while MT4336M specifically amplifies when this is a G. Since MT4336M is 20 bp longer than MT4336WT, the 4336 G variant produces a PCR product that is 20 bp longer than the PCR product generated from the 4336 A wild type sequence (fig 2) . Repeated experiments showed these primers to be specific and sensitive for both sequences. All eight people with variant AvaII restriction sites were shown to have a G at position 4336. The frequency of the tRNA Gln 4336 mitochondrial DNA mutation was determined within two community based elderly populations in East Anglia. In cohort 1 (see methods), where all subjects were aged older than 70 years, 65 pairs of demented patients and age and sex matched non-demented controls and a further 44 non-demented people were investigated. The mutation was not detected in any of the 65 demented subjects but was found to be present in 3/65 of the paired control (non-demented) samples as well as in 2/44 of the additional unmatched control samples, and was homoplasmic in all cases ( fig  1) . All five control subjects harbouring the mutation were homozygous for the E3 allele.
In cohort 2, 282 people currently aged older than 84 were screened. A Mini-Mental State (MMSE) score of 21 or less was used to define the likely presence of dementia. The mitochondrial 4336 mutation was found in 2/59 people with MMSE scores of 21 
